Blockchain Registration Transaction Record
NanoViricides Gains Approval for Ebola Phase II Trial with Oral Gummies
NanoViricides gains DRC approval for Phase II Ebola trial of NV-387 Oral Gummies, a unique oral treatment for Bundibugyo ebolavirus. Learn about this broad-spectrum antiviral and its potential impact.
This news matters because the approval of NV-387 Oral Gummies for a Phase II Ebola trial introduces a potentially game-changing oral treatment for a deadly virus, addressing critical logistical challenges in outbreak zones where IV treatments are impractical. If successful, it could provide a scalable, easy-to-administer therapy for Ebola, saving lives in resource-limited regions and reinforcing NanoViricides’ broad-spectrum antiviral platform against future pandemics.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x6d09cdd294e9533aacdd501479bd9217186b448b29afd9dcd5ce9bfbb014ce5d |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | roam0_rX-76e6367167295a34535ace0651f67bf3 |